“This is another tool available to help us arrive at an accurate diagnosis,” says Behrang Saminejad, MD, Movement Disorders Chief with the Neuroscience Institute. “It can help us rule out other neurological conditions with similar symptoms.”
Nearly 1 million people are living with Parkinson’s in the U.S., according to the Parkinson’s Foundation, and about 90,000 new Parkinson’s patients are diagnosed every year.
“There’s no simple, single test to definitively identify Parkinson’s disease,” says Dr. Saminejad. “It’s a clinical diagnosis, meaning we take symptoms, physical exam results and medical history into account when working to determine what’s at the root of a patient’s symptoms.”
Syn-One, developed by CND Life Sciences, has been available since 2019 and made medical headlines last year when a study supported by the National Institutes of Health showed the test is successful, or highly sensitive, in identifying the abnormal protein. According to CND, the test is “highly specific for a diagnosis of a synucleinopathy but does not currently distinguish between synucleinopathies.”